# US 10,946,039 B2 · Chitosan acrylic acid derivative hemostatic powder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,039 B2
- Document ID: US10946039B2
- Status: Granted
- Kind: B2
- Application number: 16/343,887
- Filed: 2017-10-25
- Published: 2020-10-01
- Granted: 2021-03-16
- Earliest claimed: 2016-10-26
- Assignees: Jiangsu NewValue Medical Products Co., Ltd.; Shnaghai Newvalue Medical Products Co., Ltd.
- Applicants: Jiangsu NewValue Medical Products Co., Ltd.; Shanghai NewValue Medical Products Co., Ltd.
- Inventors: Yingshan Zhou; Rui Jiang; Zuguang Gong; Liqin Xu; Shiming Zhou; Xiaoming Zhou
- Web page: https://patentgrep.com/patent/US10946039B2

## CPC

- A61K 31/722: Chitin, chitosan
- A61K 9/16: Agglomerates; Granulates; Microbeadlets {; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction (A61K9/20 takes precedence if the final form is a tablet; microspheres with drug-free outer coating, microcapsules A61K9/50; mixture of different granules, microcapsules, (coated) microparticles A61K9/5084; nanoparticles A61K9/51)}
- A61L 24/001: {Use of materials characterised by their function or physical properties}
- A61L 24/08: Polysaccharides {(A61L24/043 takes precedence)}
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61L 2400/04: Materials for stopping bleeding
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a hemostatic powder. The hemostatic powder is mainly present in the form of a columnar particle, wherein the ratio of axial length to diameter of the columnar particle is less than 5; the hemostatic powder includes a polymer represented by the following structural formula: wherein the R is at least one selected from the group consisting of —NH2, —OCH2CH2OH, —OCH2CH2CH2OH, —OH, —ONa, —OK and —OCa; m, n and p respectively represent number percentages of corresponding repeating units in polymer molecules, and satisfy the following equations: m+n+p=1, p/(m+n+p)=0.05˜0.30; the substitution degree D is defined as =m/(m+n+p), the overall substitution degree of the columnar particle is defined as Ds, the substitution degree of the polymer at the center point of the cross section of the columnar particle is defined as Do, and the substitution degree of the polymer at the edge of the cross section of the columnar particle is defined as Dx, and the following equations are satisfied: Ds=0.09˜0.8, Do/Dx=0˜0.7.

## Claims

### Claim 1

A hemostatic powder, comprising columnar particles, wherein the columnar particles have a axial length/diameter ratio of less than 5;
wherein said hemostatic powder comprises a polymer represented by the following structural formula:
wherein
R is at least one moiety selected from the group consisting of —NH2, —OCH2CH2OH, —OCH2CH2CH2OH, —OH, —ONa, —OK and/or —OCa;
m, n and p respectively represent numerical percentages of corresponding repeating units in the molecule of the polymer, and satisfy the following equations:
m+n+p=1,
p/(m+n+p)=0.05˜0.30;
wherein said polymer has a substitution degree D is defined as D=m/(m+n+p), and said columnar particles have an overall substitution degree is defined as Ds, and the polymer has a substitution degree at a center point of a cross section of said columnar particles defined as Do, and a substitution degree of at an edge of a cross section of said columnar particles is defined as Dx, and the following equations are satisfied:
Ds=0.09˜0.8,
Do/Dx=0˜0.7.

### Claim 2 (depends on 1)

The hemostatic powder according to claim 1, wherein R is R1 and R2, wherein R1 is from 0 to 95% of R1 and R2 is from 5 to 100% of R1,
wherein
R1 is at least one moiety selected from the group consisting of —NH2, —OCH2CH2OH and —OCH2CH2CH2OH,
and R2 is at least one moiety selected from the group consisting of —OH, —ONa, —OK and —OCa.

### Claim 3 (depends on 1)

The hemostatic powder according to claim 1, wherein Ds=0.2-0.7.

### Claim 4 (depends on 1)

The hemostatic powder according to claim 1, wherein Ds=0.3-0.6.

### Claim 5 (depends on 1)

The hemostatic powder according to claim 1, wherein Ds=0.4-0.5.

### Claim 6 (depends on 1)

The hemostatic powder according to claim 1, wherein Do/Dx=0-0.6.

### Claim 7 (depends on 1)

The hemostatic powder according to claim 1, wherein Do/Dx=0-0.5.

### Claim 8 (depends on 1)

The hemostatic powder according to claim 1, wherein Do/Dx=0-0.4.

### Claim 9 (depends on 1)

The hemostatic powder according to claim 1, wherein the polymer has a viscosity average molecular weight Mη in a range of 50, 000-10,000,000.

### Claim 10 (depends on 1)

The hemostatic powder according to claim 1, wherein the hemostatic powder has a liquid absorbing amount of 5 to 40 times of the dry weight of said powder when it absorbs physiological saline solution containing 0.9% sodium chloride.

### Claim 11 (depends on 1)

The hemostatic powder according to claim 1, wherein after the hemostatic powder absorbs liquid, the hemostatic powder has an expansion percentage along radial direction of the particles of more than 5 times of an expansion percentage along axial direction of the particles,
wherein the radial direction means a direction of a connecting line from the center of the cross section of the particles to the edge of the cross section of the particles, and
the axial direction means a direction vertical to the cross section of the particles.

### Claim 12 (depends on 1)

The hemostatic powder according to claim 1, wherein the hemostatic powder has a particle diameter of 0.2-1000 μm.

### Claim 13 (depends on 1)

The hemostatic powder according to claim 1, wherein the hemostatic powder has a ratio of axial length to diameter in a range of 0.8:1-1:0.8.

### Claim 14 (depends on 1)

The hemostatic powder according to claim 1, wherein the hemostatic powder has a bulk density of 0.5-1.2 g/cm3.

### Claim 15 (depends on 1)

The hemostatic powder according to claim 1, wherein the hemostatic powder has a degradation time in a human body or a mouse of less than 30 days.

### Claim 16 (depends on 1)

The hemostatic powder according to claim 1, wherein the hemostatic powder is prepared by pulverizing or cutting fibers.